Home › All Companies › COR › Quarterly Report

Cencora, Inc. (COR) — Quarterly Report

AI-Powered SEC Filing Analysis

← All COR filings
Latest Quarterly Report Filed: 2026-05-06

Key Insights

  • Filing dated 2026-05-06 for Q2 fiscal 2026 (ended 2026-03-31) indicates Cencora continues operating across two primary segments: US Healthcare Solutions and International Healthcare Solutions, suggesting sustained diversification in healthcare distribution.
  • Recent acquisitions including OneOncology (February 2026) and Retina Consultants of America (January 2025) demonstrate active M&A strategy to expand specialized healthcare service capabilities and market reach.
  • Presence of contingent consideration arrangements tied to business objectives for recent acquisitions indicates performance-based earnout structures, which could impact future earnings depending on achievement of specified milestones.
  • The filing structure shows multiple debt instruments outstanding (2.875% Senior Notes due 2028 and 3.625% Senior Notes due 2032), suggesting the company is managing debt obligations while funding growth initiatives through acquisitions.
Sentiment: Neutral Significance: 5/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-05-06. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Quarterly Report filings

Filed: 2026-02-04
  • The company acquired Retina Consultants of America (RCA) on January 2, 2025, which expanded its healthcare solutions segment and added intangible assets like trade names and customer relationships.
  • Cencora reported a 5% year-over-year increase in revenue for Q4 2025, driven by growth in both its US and international healthcare solutions segments.
  • The company has a diversified debt structure with a mix of senior notes, term loans, and credit facilities, which provides financial flexibility.
Sentiment: Positive Significance: 6/10
View Original Filing →

Other reports for Cencora, Inc.

Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.